(Q30414948)

English

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

Hiroyuki Fukase

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Hidetoshi Furuie

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Yuji Yasuda

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Ryoya Komatsu

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Kenji Matsushita

5

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Taketsugu Minami

6

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Yutaka Suehiro

7

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Hiroshi Yotsuyanagi

8

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Haruko Kusadokoro

9

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Hiroshi Sawata

10

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Noriko Nakura

11

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Maria Lattanzi

12

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

1 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

5030-5037

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Influenza-associated hospitalizations in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Strategies for mitigating an influenza pandemic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Recommendations for the administration of influenza vaccine in children allergic to egg.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Response to a monovalent 2009 influenza A (H1N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

A novel influenza A (H1N1) vaccine in various age groups.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Responses to 2009 H1N1 vaccine in children 3 to 17 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Oil-in-water emulsion adjuvant with influenza vaccine in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy Adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.053

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2012.03.053

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30414948&oldid=1956428249"